Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15559788 | 1.00 | MEN1 (0.51) | MEN1KMT2AHTTMAPTLMNA | |
| SCHEMBL16819994 | 0.88 | MEN1 (0.42) | MEN1KMT2AHTTMAPTLMNA | |
| SCHEMBL16845375 | 0.88 | MEN1 (0.42) | MEN1KMT2AHTTMAPTLMNA | |
| SCHEMBL15442876 | 0.87 | MEN1 (0.54) | MEN1KMT2AHTTMAPTLMNA | |
| SCHEMBL15442874 | 0.87 | MEN1 (0.54) | MEN1KMT2AHTTMAPTLMNA | |
| SCHEMBL15442878 | 0.87 | MEN1 (0.54) | MEN1KMT2AHTTMAPTLMNA | |
| SCHEMBL18938189 | 0.85 | SMN1; SMN2 (0.42) | MEN1KMT2AHTTMAPTLMNA | |
| SCHEMBL16819971 | 0.85 | HTT (0.47) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL16845420 | 0.85 | HTT (0.47) | MEN1KMT2AHTTMAPTALDH1A1 | |
| SCHEMBL16845528 | 0.85 | MAPT (0.45) | MEN1KMT2AHTTMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888229-B1 | alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2019-02-06 | — | — | EP | disclosed |
| US-9790173-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME CORP. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20150175534-A1 | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I | MERCK SHARP & DOHME CORP. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | CHRNA7, CHRNA5, CHRNA6 | MEN1 3964/4885KMT2A 2416/4885HTT 1512/4885 |
| US-20150175534-A1 | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I | CHRNA7, CHRNA6, CHRNA5 | MEN1 3873/4885KMT2A 3868/4885HTT 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.